The prevalence of chronic ulcerated wounds surpasses 8.5 million in the U.S. And Europe. Standard therapy with compression dressings or surgical products provides 50 percent to 60 percent of total venous ulcers heal within six months with a recurrence rate as high as 70 percent. The need for an effective solution is obtained annually from the health and economic costs exceed 15 billion.
Heal-Or was founded in 2002 by Dr. Tamar Tennenbaum, a life science researcher specializing in dermatology known worldwide for its research in the field of wound healing. The HO-03-03 ‘, the company’s leading product on a breakthrough technology, is effective for the treatment of three types of chronic wounds: diabetic, venous and pressure ulcers. The product showed promising results in preclinical studies and initial phase in Israel.Which company is neither responsible to update his forward-looking statements. Source: Baxter International Inc.Press published One Baxter Parkway Boca.. This press release includes forward-looking statements concerning the potential expansion of of the half-life of for rFVIII. More results including the results, customer satisfaction of regulatory and other conditions timely commencement to the clinical studies: The statements are based on assumptions about many important factors, including the below, different which could cause actual results to differ in forward – in forward – looking statements was based, humans, SEC filings, the safety and effectiveness of the product, markets acceptance for these products;? and other risks referenced company companies the recent submitting to Form 10-Q and another SEC filings, all of which is available of the company s? The website.